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Summary
Liquid biopsy represents innovation in the fi eld of oncology diagnosis. It refers to non-invasive blood collection 
 method with isolation of circulating tumor cells, cell-free DNA (with circulating tumor cell free DNA fraction), circulating 
exosomes or micro RNA. Although requires specifi c methods for isolation and analysis of targets of interest, liquid biopsy 
could be of benefi t in preoperative prediction od overall survival of patients with carcinoma, for monitoring of disease and 
progression, along with surveillance of therapy response and early recurrence of cancer. The review describes methods for 
liquid biopsy analysis, together with concerns and achievements in implementing liquid biopsy in clinical practice.
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MOGUĆNOSTI TEKUĆE BIOPSIJE U KLINIČKOJ PRAKSI
Sažetak
Tekuća biopsija predstavlja inovaciju na području onkološke dijagnostike. Neinvazivna je metoda kojom se iz uzorka 
krvi izoliraju cirkulirajuće tumorske stanice, slobodna cirkulirajuća DNA (uz frakciju tumorske DNA), cirkulirajući exosomi 
ili mikroRNA. Iako zahtjeva specifi čne metode izolacije i analize pojedinih elemenata od interesa, tekuća biopsija se može 
primijeniti u predoperativnoj predikciji preživljenja pacijenata s karcinomom, za praćenje tijeka i progresije bolesti, kao i za 
praćenje odgovora na terapiju ili ranog povratka bolesti. Članak se bavi opisom do danas poznatih metoda analize kompo-
nenata tekuće biopsije, kao i problematikom i postignućima u uvođenju tekuće biopsije u kliničku praksu.
KLJUČNE RIJEČI:  tekuća biopsija, cirkulirajuća tumorska DNA - ctDNA, cirkulirajuće tumorske stanice – CTCs, 
cirkulirajuća mikroRNA - cmiRNA, egzosomi, klinička praksa
Cancer incidence worldwide counted 14,1 
million new cases in 2012, and the number is pre-
dicted to overgrow 23 million cases each year by 
the 2030 (1). Early-stage tumor diagnosis repre-
sents leading problem in diagnosis of cancer with-
in asymptomatic population, considered „healthy“. 
Great number of tumor biomarkers are being ex-
amined nowadays, but not many have reached 
clinical practice. Sensitivity and specifi city of these 
biomarkers remain suboptimal for early-stage, or 
residual tumor diagnosis. Consequently, interest 
in tumor molecular diagnostics is rapidly increas-
ing. Up to these days tissue biopsy has been the 
gold standard for cancer diagnosis, but its limita-
tions and potential risks of complications lead to 
comprehensive search for less invasive techniques. 
The discovery of cell free DNA (cfDNA) by Man-
del and Metais in 1948 (2) and circulating tumor 
cells (CTCs) in bloodstream revealed the new era 
of molecular diagnostics of tumor diseases. Liquid 
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biopsy refers to less invasive technique which pro-
vides CTCs, cfDNA, cell free tumor DNA (ctD-
NA), circulating microRNA (cmiRNA) and exo-
somes from patient’s plasma. Development of mo-
lecular technologies such as PCR (polymerase 
chain reaction) or NGS (next generation sequenc-
ing) made analysis of ctDNA possible, in despite 
of low concentration in plasma.
Tissue biopsy and liquid biopsy- compared
Tissue biopsy provides enough material for 
pathohistological and molecular analysis giving 
information on pathohistological and molecular 
changes within tumor cells. Although it allows 
malicious and benign tumor diﬀ erentiation and 
classifi cation, it also has shortcomings. Fine or 
core needle biopsy has risks of infl ammation, tu-
mor metastasis induced by biopsy (3), (4), bleed-
ing, or other complications, also it is painful for 
patient. Further biopsies during treatment are of-
ten impossible to be done due to the risks listed. 
Another disadvantage of tissue biopsy is aﬀ ord-
ability as it is performed by experienced profes-
sional and is usually guided by ultrasound, com-
puted tomography scan (CT scan) or mammogra-
phy. CT guided fi ne needle aspiration biopsy cost 
for lung cancer patients was presented in a study. 
The cost (including procedure, adverse events and 
pathology tests) was $4130,09 on average, while 
blood-based genome test (including blood draw 
and pathology tests) summed up to $836,45. An-
other tissue biopsy disadvantage of concern is 
turnaround time (TAT); while DNA analysis re-
sults can be obtained within 71 hours from blood 
collection, biopsy results are usually given within 
1 or 2 weeks from sampling. Molecular analysis 
obtained from formalin-fi xed paraﬃ  n-embedded 
(FFPE) tissue sample has weaknesses; non-stan-
dardized preparation methods and toxic fi xatives 
induce DNA degradation, thus DNA integrity 
verifi cation is necessary prior to molecular analy-
sis (5). As it grows, tumor mutates and tumor tis-
sue becomes molecularly heterogeneous – one 
needle aspiration can hardly collect all types of 
tumor cells, and sometimes re-aspiration is need-
ed -this is where liquid biopsy is welcomed. False 
negative pathohistological or cytological results of 
patients with early-stage cancer can be conse-
quence of imprecise needle aspiration. On the con-
trary, ctDNA can be found in some patients with 
early-stage cancer disease and can detect residual 
lesions following therapy. High sensitivity and 
specifi city of ctDNA analytical methods can help 
diagnose and monitoring of invasive cancer in 
early stage, together with recurrence of the cancer.
Characteristics of liquid biopsy compounds
CTCs-circulating tumor cells
Origin of CTCs can be primary tumor or sec-
ondary metastatic sites. Detached cancer cells 
have a role in metastasis through blood circula-
tion. CTCs found in blood have epithelial /mesen-
chymal tumor origin and express epithelial mark-
ers on their surface (6) for example EpCAM 
(Epithelial Cell Adhesion Molecules) or CDH2 
(Cadherin-2, N-cadherin) – a molecule included in 
cell-to-cell adhesion and transendothelial metas-
tasis of cancer cells (7). Epithelial tumor cells go 
through epithelial to mesenchymal transition 
(EMT) - changing surface molecules and weaken-
ing intercellular adhesion. This process aﬀ ects the 
success of the isolation of CTCs using antibodies 
targeting epithelial surface molecules. Transition-
al cells gain the ability to survive inside blood-
stream and invade distance tissue. Adhesion of 
CTCs and progression of metastatic cancer de-
pend on optimal fl ow of blood - “mechanic hy-
pothesis” and local microenvironment of the ad-
hesion site – the “seed and soil” hypothesis (8).
Great number of researches had shown correla-
tion evidence between blood fl ow patt ern and me-
tastasis of primary tumor cells. CTCs (mean diam-
eter of 12 to 20 μm) are usually trapped inside 
capillaries of lungs and liver (diameter 3-8 μm), or 
other capillary perfused organs (7). CTCs need to 
escape anoikis (programmed cell death that oc-
curs when cells detach from the surrounding ex-
tracellular matrix) and immune system defence 
prior to metastasis (9). Some of these mechanisms 
include clustering with other cells, such as plate-
lets -“cloaking eﬀ ect” while other mechanisms are 
yet to be described. Platelets and monocytes 
(found in CTC clusters) and macrophages mediate 
adhesion and thrive the metastatic progress 
(10,11). Value of CTCs number clinically correlates 
with invasive progression of cancer, tumor mass 
and decreased overall survival in patients with 
diﬀ erent cancer varieties. Using diﬀ erent plat-
forms circulating tumor cells can be suﬃ  ciently 
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separated from other blood cells, despite the low 
count in which they are found (1 CTC per 106 – 108 
white blood cells or 0-10 CTC/mL of blood (12)). 
Single tumor cells can be isolated using EpCAM 
expressed on their surface, or can be separated by 
size using microporous fi lter membranes, since 
CTCs are bigger in size in relation to blood cells. 
Isolated cells can be characterized by immunos-
taining of cytokeratin or other specifi c molecules 
expressed in tumor cells. On the other hand, clus-
ters of CTCs, which have higher metastatic poten-
tial, can be separated physically using microfl u-
idic bifurcating traps (13). Morphological charac-
teristics defi ne best isolation methods to be used 
in particular research purposes.
ctDNA – cell free tumor DNA
ctDNA can be isolated from plasma or serum 
of cancer patients, together with other cell-free 
DNA. Short half-life of ctDNA in blood (~ 2 hours) 
refl ects real-time tumor stage(14), and can be clin-
ically used to monitor tumor progression or treat-
ment eﬃ  cacy, while some protein biomarkers cir-
culate in bloodstream for several weeks. Con-
centration range of cfDNA in healthy individuals 
is 0-35 ng/mL while numbers can exceed 1000 ng/
mL in cancer patients group. Depending on can-
cer stage and metastasis ctDNA varies from 0,01% 
to >90% of cfDNA concentration (15). ctDNA can 
be either single- or double-stranded DNA, with 
apoptotic or necrotic tumor cell origin, or can be 
spontaneously released into the bloodstream by 
living tumor cells in the form of nucleosomes. Dif-
ferent studies fi nd ctDNA shorter than non-cancer 
cell free DNA, while some fi nd it opposite – diﬀ er-
ent conclusions can be linked to the variations of 
detection methods. The approximal length of ctD-
NA fragment (around 166 bp) indicates its apop-
totic origin, during apoptosis DNA is cleaved in 
between nucleosomes at ~ 180 bp intervals (the 
endonuclease cleavage leaves “ladder-like” pat-
tern on gel electrophoresis). Other evidences sup-
port hypothesis of CTCs as one of the ctDNA 
sources in blood, since mutations found in ctDNA 
are identical to the ones found in CTC from the 
same patient sample(16). Tumor tissue biopsy re-
sults can prove ctDNA origin; point mutations, 
copy number variations or chromosome aberra-
tions as well as epigenetic molecular changes 
(DNA methylation, sulfonation) or cancer derived 
viral sequences found in ctDNA will be identical 
to tumor cell-DNA biopsy, if the samples were 
taken properly. Garcia-Olmoand coworkers es-
tablished the hypothesis of genometastasis in 1999 
with remarkable discovery of cancer transforma-
tion of cultured cells induced by addition of plas-
ma taken from tumor bearing rats (17). The fol-
lowing studies demonstrated oncogenic transfor-
mation of susceptible cultured cells caused by 
addition of plasma containing ctDNA obtained 
from colorectal carcinoma (CRC) patients (18). 
Trejo-Becerril et al. brought evidence to the hy-
pothesis of genometastasis with research showing 
the ability of ctDNA to prompt horizontal tumor 
progression in an immunocompetent colon-carci-
nogenesis rat model (19). Oncogenic transforma-
tion of cells did not occur when serum and super-
natants were depleted of DNA, thus confi rming 
tumorigenic characteristics of ctDNA. The mecha-
nism of ctDNA uptake by the host cells remains 
unclear. Few studies point out circulating apop-
totic bodies as primary source of ctDNA, while 
others suggest DNA/RNA complexes (“virto-
somes”) as one of the forms in which ctDNA is 
taken by host cell (15).
Exosomes
Exosomes are microvesicles (3-200 nm in size) 
containing RNA, proteins and lipids inside lipid 
membrane. Physiological function of exosomes 
circulating in blood is communication and trans-
fer of molecules between distant cells. Tumor cells 
use exosomes for stimulation of cell proliferation, 
angiogenesis and metastasis. On the molecular 
point of view, exosomes released by tumor cells 
carry highly specifi c molecular patt erns and con-
tribute to the detailed study of cancer metabolism. 
A study presented specifi c molecule – glypican-1 
(GPC1(+)) isolated from circulating exosomes 
found in serum of patients with pancreatic cancer. 
This molecule had absolute specifi city and sen-
sitivity for distinguishing healthy subjects and 
patients with a benign pancreatic disease from 
patients with early- and late-stage pancreatic can-
cer (20).
cmiRNA – circulating micro RNA
cmiRNA can be found inside exosomes or in 
a free-form released into bloodstream by tumor or 
other cells (21). RNA is fragile molecule, and re-
quires RNase inhibitors and RNase free equip-
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ment in order to avoid destruction during isola-
tion and sample manipulation. However, miRNAs 
are relatively stable in blood containing RNases 
(necessary for viral RNA degradation), but the 
mechanism of RNase circumvention remains in-
distinct (21). miRNAs are single-stranded, non-
coding RNA molecules that are 20-23 nucleotides 
long and have a role in silencing mRNA and post-
transcriptional regulation of gene expression, while 
specifi c cmiRNA patt erns can be found in cancer 
patients (22) such as circulating miR-21 which can 
be used as potential tumor biomarker in CRC (23).
TEP-tumor educated platelets
One of the cells that also participates in tu-
mor growth and dissemination and aﬀ ects their 
gene expression are platelets. RNA profi le of 
blood platelets is infl uenced by tumor type, pro-
gression and metastasis as tumor alerts premRNA 
splicing. TEPs provide specifi c information on the 
location and characteristics of primary tumor. In 
283 patients, Best et al. (24) have done TEPs mRNA 
sequencing and diﬀ ered patients with primary tu-
mor and metastasis from healthy ones with 96 % 
accuracy. Location of primary tumor was correct-
ly identifi ed in 71% of patients and diﬀ erent muta-
tions were described. TEPs isolation should be 
done within 48 hours after blood collection, but 
the risk of change in mRNA profi le increases dur-
ing that period. Diseases other than cancer can 
also alert platelet mRNA profi le, however, larger 
studies are required on this subject.
Methodologies in liquid biopsy analysis
The selection of method should be made re-
garding the purpose of the analysis; it is hard to 
fi nd optimal method to be used in clinical routine 
due to complex nature of liquid biopsy analytes. 
Diﬀ erent methods may be required for early-stage 
recognition and monitoring therapy eﬃ  cacy. For 
example: CTCs can be isolated intact and cultivat-
ed for further therapy analysis but the method 
could be time consuming, while ctDNA concen-
tration analysis, which can help monitoring tumor 
progression, could be done within hours. In the 
fi eld of liquid biopsy, numerous researches are 
struggling with method optimization and pre-an-
alytical phase requests, which have to be met for 
successful analytical phase. Nowadays, next gen-
eration sequencing (NGS), pyrosequencing and 
other similar methods bring improvement and ad-
vances in cancer research and post-analytical 
phase, making it easier for clinicians to interpret.
Pre-analytical phase
The Biomarkers Consortium Workshop held 
in 2010 brought together the experts in the fi eld of 
CTC research to share experience and compare 
the performances of most promising assay tech-
nologies with aim to take initial step in clinical 
validation of these  methods (25). In order to enter 
clinical practice, pre-analytical phase variables 
should be standardized for each assay – sample 
acquisition, processing, storage and transport 
conditions should be defi ned.
CTCs pre-analytical requirements:
Liquid biopsy requires 5 to 10 mL of blood 
taken on anticoagulant EDTA tubes used for blood 
collection need to be processed within 24 hours of 
blood collection to minimize cell degradation. 
Procedures can diﬀ er regarding stability, size and 
concentration in plasma in dependence of exam-
ined CTCs and method used.
cfDNA/ ctDNA pre-analytical requirements
Since ctDNA builds up a fraction in circulat-
ing cell free DNA, cfDNA should be isolated in 
order to analyse ctDNA. Isolation from plasma or 
serum sample is performed using isolation kits; 
shipping, storage or quality of sample, however, 
can aﬀ ect isolation’s eﬃ  ciency. Blood cell degra-
dation in pre-analytical phase can contaminate the 
sample with genomic DNA. Manufacturers give 
instructions on sample acquisition, processing 
and storage - tested and optimized in studies that 
preceded putt ing the isolation kit on market. Some 
manufacturers even examined the infl uence of 
shaking and storage conditions in a way of con-
tamination with genome DNA in plasma collected 
in preservative tubes which they made for this 
purpose especially, and compared it to other com-
mercially available K2EDTA tubes.
cmiRNA pre-analytical requirements
Studies on miRNA confi rmed advantages of 
plasma over serum samples (26). During clot pro-
cess required for serum, non-specifi c miRNA is 
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released from platelets, lysed red blood cells, leu-
kocytes, and circulating tumor cells, contaminat-
ing the cmiRNA. Plasma is collected in tubes con-
taining standard blood anticoagulants: EDTA or 
sodium citrate followed by centrifugation. Hepa-
rin anticoagulant might interfere with analytic 
methods (inhibits polymerase and reverse tran-
scriptase enzymes used in PCR), therefore, hepa-
rin tubes are not recommended (27). Standard 
protocol for sample handling and storage of miR-
NA samples have yet to be made, however, cryo-
preservation on -80°C reduces degradation during 
long-term storage. All limitations listed can aﬀ ect 
the interpretation of miRNA results; therefore, 
standardized protocols are indispensable.
Analytical phase
Clinical practice has set the bar high when 
discussing analytical phase requirements; high 
sensitivity (with low limit detection) and specifi c-
ity are of main importance, especially for tumor 
biomarkers since diagnostic criteria and therapeu-
tic protocols depend on biomarker results. Report-
able ranges have to be set prior to clinical use of 
tumor marker, unfortunately, cancer diagnosis is 
sometimes hard to set due to complexity of cancer, 
and tumor biomarkers cannot be easily put in be-
tween range boundaries. Assay reproducibility 
and robustness required for routine work repre-
sent one of the main diﬃ  culties in implementing 
liquid biopsy in everyday clinical practice.
CTCs
CTCs assay technologies used in process are 
determined by target cells and assay outcome- 
characterization, enumeration or enrichment. Im-
munoassays are widely used in detection and en-
richment of rare CTCs. Specifi c antigen-antibody 
reaction allows isolation of EpCAM+, CD45-, 
HER2/neu+ or other tumor cells, following purifi -
cation can be performed with immunomagnetic 
beads or columns. Downstream processes usually 
include fl uorescent antibodies staining and label-
ling of intracellular components and confocal mi-
croscopy. Other technologies are based upon CTC 
size, for example, CTC Membrane Microfi lter is 
designed to exploit cell size diﬀ erences between 
normal blood cell and tumor cells and following 
characterization of the tumor cell is done by quan-
tum dot-based immunofl uorescence detection 
(28). If viable, intact cells are required for cultiva-
tion or other analysis, size based vacuum fi ltration 
would be a method of choice, e.g. ISET (Isolation 
by Size of Epithelial Tumor cells) and Nucleopore 
Assay methods. Flow cytometry is also one of 
technologies with wide application in CTC analy-
sis. Some technologies took a step forward and 
exploit diﬀ erences in density and dielectric prop-
erties for diﬀ erentiation of cells (Dielectroforetic 
Field Flow Fractionation – DFFF). Extraordinary 
assays use nanodetectors binding EpCAM+ cells 
in vivo, or even noninvasively count CTCs by in-
jection of tumor-specifi c fl uorescent ligand fol-
lowed by multiphoton fl uorescence imaging of 
superfi cial blood vessels to quantitate the fl owing 
CTCs. CTC undergoing EMT can be separated us-
ing negative enrichment – red cells are lysed and 
CD45+ cells (leukocytes) removed by immuno-
magnetic beads, but still have to be distinguished 
from remaining epithelial cells. Manifold technol-
ogies are used in but still have not reached clinical 
practice.
cfDNA
cfDNA is isolated from plasma using special-
ized DNA isolation kits prior to ctDNA analysis– 
numerous articles compared diﬀ erent commer-
cially available kits (29) (e.g. QIAamp® circulating 
nucleic acid kit (QIA - Qiagen), PME free-circulat-
ing DNA Extraction Kit (PME - Analytik Jenna), 
MagTMcfDNA Isolation Kit (NpM - BiooScientif-
ic)). Steps following isolation include measure-
ment with quantitative PCR – qPCR (based on 
fl uorescence of probes att ached to amplifi ed DNA 
segments), digital droplet PCR (ddPCR), quan-
titative kits for measuring cfDNA concentration 
(based on fl uorescence and standard curve) or se-
quencing of cfDNA fragments (using NGS, pyro-
sequencing or other methods). Sequencing usual-
ly requires pre-amplifi cation of cfDNA and library 
construction using multiple-primer reaction. Ion 
Torrent™ technology by ThermoFisher Scientifi c 
is platform that allows generating gigabases of se-
quence per day, and enables new experiments on 
complementary DNA (cDNA) sequencing. This 
technology directly translates chemically encoded 
information (A, C, G, T) into digital information 
(0, 1) on a semiconductor chip, resulting in sim-
pler, faster, more cost-eﬀ ective and scalable next-
generation sequencing. Technology evolution and 
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widening of gene databases contributes to screen-
ing and early recognition of cancer diseases; cfD-
NA/ctDNA and NGS have potential to dramati-
cally change diagnostic, monitoring and treatment 
of cancer once used in clinical practice, as con-
cluded on Circulating Tumor Cells (CTC) and 
Cell-Free DNA (cfDNA) Workshop 2016: Scientif-
ic Opportunities and Logistics for Cancer Clinical 
Trial Incorporation conference (30).
cmiRNA
Previous isolation of RNA included multiple 
extraction steps with analyte loss and long dura-
tion of the process. Phenol-chloroform extraction 
(Trizol) required a large sample volume and in-
cluded working with toxic reagents, but recently 
several isolation kits become commercially avail-
able for research purposes. MiRCURY™ RNA Iso-
lation Kit (Exiqon, Denmark), mirVana™ PARIS™ 
(Life Technologies, Grand Island, NY, USA) and 
miRNeasy® (Qiagen, Venlo, Limburg, Belgium) 
made isolation of miRNA aﬀ ordable, easy and 
practical. The amount and quality of isolated ma-
terial could not be compared between these kits 
since the reports on this subjects haven’t been 
done yet. Quantifi cation of cmiRNA extracted can 
be done using spectrophotometer, but due to low 
amounts of cmiRNA, more sensitive technologies 
are required. Agilent Technologies 2100 Bioana-
lyzer (Agilent, Santa Clara, CA, USA) uses capil-
lary electrophoresis to assess miRNA concentra-
tion (31). The integrity of isolated RNA represents 
another problem in miRNA analysis – degraded 
RNA is not a suitable analyte for NGS or microar-
ray analysis. Reverse transcriptase PCR (RT-qP-
CR) is a method of choice for miRNA analysis 
measuring changes of gene expression to a suit-
able internal control. This is the “weak point” of 
RT-qPCR method, since few endogenous microR-
NAs can be used as an internal control to evaluate 
cmiRNA multiplication. This is due to variations 
of microRNA expression in several diseases and 
among individuals (32). Exogenous control refers 
to artifi cial microRNAs added to the samples pri-
or to RNA extraction, but can contaminate prima-
ry samples, and it is diﬃ  cult to control the amount 
of external RNA added to each sample. These dis-
advantages can be circumvented using standard 
curves for each microRNA. Unfortunately, this is 
an expensive, time-consuming method with ques-
tionable stability of stock sample used in generat-
ing curves. Microarray assay methodologies allow 
wide gene profi ling, but require software systems 
for imaging and data analysis (31) and cannot be 
used for miRNA quantifi cation due to low speci-
fi city and sensitivity. 3D-Gene® microarray pro-
duced by Toray (Tokyo, Japan) is improved, high-
ly sensitive and reproducible assay expanding the 
horizon for miRNA analysis. Massive parallel se-
quencing was a complex method of miRNA anal-
ysis including RNA extraction and size fraction-
ation of the small RNA, conversion to cDNA and 
PCR multiplication together with library construc-
tion. It is replaced by the HTG EdgeSeq system 
(HTG molecular, Tuscon, AZ, USA) which relies 
on the specifi city of the pre-designed probes. 
Currently it is ongoing validation to determine 
specifi city and sensitivity in detecting cmiRNA. 
The advantages of HTG EdgeSeq: highly auto-
mated protocol (with reduced user variations), 
adjusted sample preparation and input require-
ments, large number of targeted miRNAs 
(>2000), needless RNA extraction and absence of 
molecular library made it revolutionary in miR-
NA analysis.
The future of liquid biopsy in clinical practice
Liquid biopsy has been introduced in clini-
cal practice through prenatal screening tests, 
and consequently showed great potential to be 
implanted in other fi elds, especially for diagno-
sis and monitoring of cancer disease. Detection 
of specifi c mutations, overall survival predic-
tion, recurrence of disease, cultivation of CTCs 
for further pharmacotherapy and therapeutic 
targeting, as well as monitoring of therapy re-
sponse can be provided from ctDNA and CTCs 
– the most frequently used liquid biopsy com-
pounds.
CTCs are detectable in 60 % of metastatic 
breast and prostate cancers, while lower abso-
lute number is found in metastatic CRC cancer 
(~ 30 – 40% of cases) (33). The explanation for 
this event can be found (could be) in circulatory 
anatomy of intestine and hepatic drainage, 
which prevents/disables CTCs to reach periph-
eral blood. However, in patients with advanced 
solid tumors, ctDNA was present even when 
CTCs were not detectable. The detection and 
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enumeration of CTC cells can be used in progno-
sis of disease and prediction of disease-free and 
overall survival. FDA approved CellSearch® 
(Veridex, New Jersey, USA) Circulating Tumor 
Cell Kit for enumeration based on EpCAM+ an-
tibodies. Specifi city of antibodies, however, can 
vary and the detection rate can be greatly 
changed (34). This has to be considered when in-
terpreting the result. Consequently, serial CTC 
testing using CellSearch® should be used to-
gether with other clinical methods for monitor-
ing metastatic breast, colorectal, and prostate 
cancer. CTC go through dynamic changes in tu-
mor progression, therefore characterization of 
EMT features can detect tumor cells resistance to 
given therapy (35). CTCs obtained from patient 
before surgery can help predict the overall sur-
vival, but more importantly CTCs obtained after 
surgical therapy can help guide therapeutic de-
cision (36), which represents an endless chal-
lenge for oncologists worldwide.
ctDNA gives real-time information on mo-
lecular changes inside growing tumor including 
copy number aberrations and other somatic mu-
tations and deletions. Clinical correlation of ctD-
NA and tumor burden depends on tumor stage, 
localization and type. Another study detected 
ctDNA in 48-73% patients with gastrointestinal 
cancer, while all patients with metastatic GI can-
cer had higher levels of ctDNA (36). Circulating 
tumor DNA can be used in screening for CRC; 
FDA approved EpiProColon blood-based test 
that identifi es methylated Septin 9 DNA. High 
preoperative ctDNA concentration is associated 
with poorer prognosis and shorter overall sur-
vival. Postoperative ctDNA is more reliable and 
sensitive for detection of tumor recurrence than 
other tumor biomarkers, such as CEA (carcino-
embryonic antigen) in CRC or CA 15-3 (cancer 
antigen 15-3) in breast cancer. Patients were fol-
lowed for 2 years after surgery: the disease reoc-
curred in 85% patients with detectable postsur-
gical ctDNA levels while 100% patients with un-
detectable ctDNA were recurrence-free. ctDNA 
can identify patients with higher risk of recur-
rence and help guide adjuvant therapy. Chemo-
therapy or radiotherapy cause extensive ctDNA 
release, but it is unclear if ctDNA is released 
from dying cells or higher levels of ctDNA are 
consequence of cancer resistance to therapy. An-
other disadvantage of ctDNA is discorrespon-
dance between expressed phenotype and detect-
ed genotype (not all of the mutations found take 
part in cancer pathogenesis). From analytical 
point of view, ctDNA is reliable, stable and eas-
ily isolated analyte, but requires a priori knowl-
edge and target of interest for clinical practice.
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